Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.
Autoimmune lymphoproliferative syndrome (ALPS) is a variable clinical condition manifest by lymphoproliferative disease, autoimmune cytopenias and susceptibility to malignancy. Central to the cellular pathogenesis is defective FAS-induced apoptosis, which in turn leads to dysregulation of lymphocyte homeostasis. The majority of patients have heterozygous mutations in the FAS (TNFRSF6) gene, but the condition is genetically heterogeneous and mutations in FAS ligand and caspase-8 and caspase-10, all of which are involved in Fas mediated signalling, have also been identified. This review provides a detailed insight into the pathophysiology of lymphocyte apoptosis and how this relates to the variable and complex clinical manifestations of ALPS.
Worth
Austen
A
Department of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UK.
Thrasher
Adrian J
AJ
Gaspar
H Bobby
HB
D017209:Apoptosis; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D006801:Humans; D008214:Lymphocytes / Q000502:physiology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D010641:Phenotype; D019014:fas Receptor / Q000235:genetics
D019014:fas Receptor